Skip to Main Content

Paper Details

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
J Clin Oncol
17
2023
Cancer, Cediranib, HRR, Metastatic Castration-Resistant Prostate Cancer, Olaparib, Patients, cediranib, homologous recombination repair, homologous recombination repair (HRR) genes, mCRPC, men, metastatic castration-resistant prostate cancer, olaparib, patients, poly-(ADP-ribose), prostate cancer, vascular endothelial growth factor receptor
Author NameAffiliation
Mary-Ellen TaplinDana-Farber Cancer Institute and Harvard Medical School
Primo N LaraUC Davis Comprehensive Cancer Center
Eliezer M Van AllenDana-Farber Cancer Institute and Harvard Medical School
Eliezer M Van AllenDana-Farber Cancer Institute and Harvard Medical School
Serhan UnluMedical Oncology Yale School of Medicine and Yale Cancer Center
Massimo Lodaand Meyer Cancer Center
  • 1 - 6

Datasets

Release 1.2